Yalçın-Ülker, Gül MerveGünbatan, MuratDuygu, GoncaSoluk-Tekkesin, MervaÖzçakir-Tomruk, Ceyda2023-05-062023-05-0620232227-9059https://doi.org/10.3390/biomedicines11030758https://hdl.handle.net/20.500.11776/11931This experimental study investigates the prophylactic effect of deferoxamine (DFO) on medication-related osteonecrosis of the jaw (MRONJ). Thirty-six female Sprague Dawley rats received zoledronic acid (ZA) for eight weeks to create an osteonecrosis model. DFO was locally applied into the extraction sockets with gelatin sponge (GS) carriers to prevent MRONJ. The specimens were histopathologically and histomorphometrically evaluated. Hypoxia-inducible factor 1-alpha (HIF-1 alpha) protein levels in the extraction sockets were quantified. New bone formation rate differed significantly between groups (p = 0.005). Newly formed bone ratios in the extraction sockets did not differ significantly between the control group and the GS (p = 1), GS/DFO (p = 0.749), ZA (p = 0.105), ZA-GS (p = 0.474), and ZA-GS/DFO (p = 1) groups. While newly formed bone rates were higher in the ZA-GS and ZA-GS/DFO groups than in the ZA group, the differences were not significant. HIF-1 alpha levels differed significantly between groups (p < 0.001) and were significantly higher in the DFO and ZA-GS/DFO groups than in the control group (p = 0.001 and p = 0.004, respectively). While HIF-1 alpha levels were higher in the ZA-GS/DFO group than in the ZA group, the difference was not significant. While HIF-1 alpha protein levels and new bone formation rate were elevated in the DFO-treated group, the effect was not significant. Further large-scale studies are needed to understand DFO's preventative effects on MRONJ and the role of HIF-1 alpha in MRONJ pathogenesis.en10.3390/biomedicines11030758info:eu-repo/semantics/openAccessbisphosphonatedeferoxaminehypoxia-inducible factor 1-alphamedication-related osteonecrosis of the jawtooth extractionBisphosphonate-Related OsteonecrosisPlatelet-Rich FibrinGene-ExpressionGrowth-FactorsAngiogenesisPamidronateRegenerationZoledronateAlendronateFractureArticle113Q1WOS:0009542591000012-s2.0-8515153031336979736Q1